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follicles per cyst. The control experi-
ment that has no lentivirus infection (no
lentivirus) induced 37±18.9 hair folli-
cles per cyst.
In summary, we found that OVOL1 of
mouse neonatal dermal cells has a critical
role in hair follicle neogenesis, which has
not been previously reported. In view of
the fact that OVOL1 is a transcription
factor, genes targeted by OVOL1 are
believed to be involved in hair neogenesis.
All animal experiments were con-
ducted in accordance with guidelines
and approval of the institutional animal
care and use committee at Kyungpook
National University.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This research was supported by the Basic Science
Research Program through the National Research
Foundation of Korea (NRF) funded by the Ministry
of Education, Science and Technology (NRF-
2012R1A1B3001047).
Seung H. Shin1, Daehwan Kim2,3,
Joonsung Hwang2, Moon K. Kim1,
Jung C. Kim1 and Young K. Sung1
1Department of Immunology and Hair Research
Center, School of Medicine, Kyungpook
National University, Daegu, Korea; 2World
Class Institute, Korea Research Institute of
Bioscience and Biotechnology, Ochang, Korea
and 3University of Science and Technology,
Daejeon, Korea
E-mail: ysung@knu.ac.kr
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Dai X, Schonbaum C, Degenstein L et al. (1998)
The ovo gene required for cuticle formation
and oogenesis in flies is involved in hair
formation and spermatogenesis in mice.
Genes Dev 12:3452–63
Enshell-Seijffers D, Lindon C, Kashiwagi M et al.
(2010) beta-catenin activity in the dermal
papilla regulates morphogenesis and regen-
eration of hair. Dev Cell 18:633–42
Ito Y, Hamazaki TS, Ohnuma K et al. (2007)
Isolation of murine hair-inducing cells using
the cell surface marker prominin-1/CD133.
J Invest Dermatol 127:1052–60
Kishimoto J, Burgeson RE, Morgan BA (2000)
Wnt signaling maintains the hair-inducing
activity of the dermal papilla. Genes Dev
14:1181–5
Li B, Mackay DR, Dai Q et al. (2002) The LEF1/
beta -catenin complex activates movo1, a
mouse homolog of Drosophila ovo required
for epidermal appendage differentiation. Proc
Natl Acad Sci USA 99:6064–9
Ohyama M, Zheng Y, Paus R et al. (2010) The
mesenchymal component of hair follicle neo-
genesis: background, methods and molecular
characterization. Exp Dermatol 19:89–99
Osada A, Iwabuchi T, Kishimoto J et al. (2007)
Long-term culture of mouse vibrissal dermal
papilla cells and de novo hair follicle induc-
tion. Tissue Eng 13:975–82
Shimizu H, Morgan BA (2004) Wnt signaling
through the b-catenin pathway is sufficient
to maintain, but not restore, anagen-phase
characteristics of dermal papilla cells. J Invest
Dermatol 122:239–45
Yang CC, Cotsarelis G (2010) Review of hair
follicle dermal cells. J Dermatol Sci 57:2–11
Young TH, Lee CY, Chiu HC et al. (2008) Self-
assembly of dermal papilla cells into induc-
tive spheroidal microtissues on poly(ethylene-
co-vinyl alcohol) membranes for hair follicle
regeneration. Biomaterials 29:3521–30
Zheng Y, Du X, Wang W et al. (2005) Organogen-
esis from dissociated cells: generation of
mature cycling hair follicles from skin-derived
cells. J Invest Dermatol 124:867–76
Zheng Y, Nace A, Chen W et al. (2010) Mature
hair follicles generated from dissociated cells:
a universal mechanism of folliculoneogenesis.
Dev Dyn 239:2619–26
Changing Incidence Trends of Cutaneous B-Cell Lymphoma
Journal of Investigative Dermatology (2014) 134, 840–842; doi:10.1038/jid.2013.393; published online 17 October 2013
TO THE EDITOR
The incidence of cutaneous B-cell
lymphoma (CBCL) has been increasing
over decades, with a recent (2001–2005)
overall annual age-adjusted incidence
rate of 3.1 cases per million persons
(Bradford et al., 2009). We sought to
measure incidence trend changes in
CBCL using population-based data.
Incidence data were derived from the
nine original registries of the Surveil-
lance, Epidemiology, and End Results
(SEERs) program of the National Cancer
Institute from 1973 to 2010. Cases of
CBCL were defined according to the
International Classification of Diseases
for Oncology, third edition (ICD-O-3).
The primary site of involvement was
coded for skin (44.0–44.9). CBCL diag-
noses were coded as the following: small
B-lymphocytic non-Hodgkin’s lymphoma
(NHL), nitric oxide synthase (NOS;
9670), lymphoplasmacytic NHL (9671),
mantle cell lymphoma (9673), diffuse
large B-cell NHL (9680), immunoblastic
diffuse large B-cell NHL (9684), Burkitt
lymphoma NOS (9687), follicular lym-
phoma NOS (9690), follicular lym-
phoma grades 1–3 (9691, 9695, 9698),
and marginal-zone B-cell lymphoma
NOS (9699). Institutional review board
approval was not required.
Data were analyzed using SEER*Stat
version 7.0.5 of the National Cancer
Institute and Stata SE version 8
(StataCorp, College Station, TX). Inci-
dence rates were adjusted according to
age using the 2000 US standard popula-
tion and are reported per million per-
sons. Trends for CBCL were analyzed
using the JoinPoint regression program
4.0.1 (National Cancer Institute). A join-
point year refers to the year in which a
statistically significant change in inci-
dence trend is found.
CBCL incidence has steadily
increased from 0.65 per million persons
between 1973 and 1980 to an average
annual rate of 3.70 between 2001 and
2005 and to 3.92 between 2006 and
2010, Po0.001 (Table 1). This increase
was statistically significant in all tested
subgroups including race, age, and gen-
der and registry.
Despite an overall increase in CBCL
incidence over the past few decades,Accepted article preview online 13 September 2013; published online 17 October 2013
Abbreviations: APC, annual percentage change; CBCL, cutaneous B-cell lymphoma; CI, confidence
interval; CL, cutaneous lymphoma; NHL, non-Hodgkin’s lymphoma
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increases in CBCL incidence appear to
be stabilizing. We observed a joinpoint
year in 2003 (95% confidence interval
(CI) 1997 to 2005; Figure 1). From 1973
to 2003, CBCL incidence had been
increasing by 6.9% (95% CI 5.8 to 7.9)
annually, but, from 2003 to 2010, the
annual percentage change (APC) was
0.3% (95% CI  4.1 to 4.9).
This trend was also seen in diffuse
large B-cell lymphoma alone, the most
common diagnosis within the CBCL
grouping. Stabilization of incidence
within this subgroup occurred in 2001
(95% CI 1993 to 2004), as the incidence
increased until that point (APC 4.9 95%
CI 3.3 to 6.5) and was not significantly
different from 0 after it (APC 3.9, 95%
CI 8.6 to 1.0). A similar pattern was
observed in several other subgroups. A
joinpoint was observed for whites in
2003 (95% CI 1998 to 2006) with an
APC of 7.0% before 2003 (95% CI 5.9
to 8.1) and an APC of 0.6% after 2003
(95% CI  3.9 to 5.3). For male indivi-
duals, a joinpoint was found in 2003
(95% CI 2001 to 2006) with an APC of
7.5% from 1973 to 2003 (95% CI 6.0 to
9.0) and that of  0.8% from 2003 to
2010 (95% CI 6.0 to 4.7). The inci-
dence in the female population contin-
ued to increase without any trend
changes. We were unable to assess for
trend changes in racial subgroups other
than whites, age groups, CBCL diag-
noses other than diffuse large B cell, or
registry due to small numbers of cases.
We have demonstrated a stabiliza-
tion of CBCL incidence in the setting
of a documented increase over decades
(Smith et al., 2005), a trend that was
consistent during the analysis of several
subgroups. This stabilization has been
suggested but not studied extensively.
Bradford et al. (2009) reported that inci-
dence rates of cutaneous lymphomas
(CLs) overall have begun to decrease
during 2001 to 2003 through 2004 to
2005.
We propose several reasons for the
trend change, including a true stabili-
zation in incidence as well as artifact
including delayed reporting. Over the
past few decades, collaborative studies
on CL have resulted in definitions of
new types of CBCLs and the develop-
ment of consensus classifications for
primary CLs (Willemze et al., 2005;
Willemze, 2012). Thus, our understan-
ding of CBCL has grown enormously. To
explain our findings, the rate of conti-
nued improvements in CBCL diagnosis
in the community may be slowing down
and reaching a natural maximum.
However, changes in registration pose
significant issues. Many primary cuta-
neous diffuse large B-cell lymphomas
have most recently been classified as
primary cutaneous follicle center
lymphoma. This would explain the
decreased incidence of diffuse B-cell
lymphoma, and concomitant increases
in follicle center lymphoma would be
expected. If true, findings that support
this explanation should become more
evident in the future. In addition, data
from the early years of SEER may not
be reliable. Before 1990, primary cuta-
neous B-cell lymphomas were not clas-
sified as CBCL, and thus early increases
in incidence may have been due to
underreporting rather than biological
causes. This is supported by the fact
that the incidence of CBCL from 1989
to 2005, in countries such as the
Netherlands that have very
Table 1. Cutaneous B-cell lymphoma incidence rates per million persons
(overall and by subgroups) from nine Surveillance, Epidemiology, and End
Result registries, from 1973 to 2010
1973–
1980
1981–
1985
1986–
1990
1991–
1995
1996–
2000
2000–
2005
2006–
2010 Ptrend
Overall
incidence
0.65 1.02 1.59 1.88 2.70 3.70 3.92 o0.001
Age
0–54 years 0.18 0.39 0.76 0.70 1.05 1.42 1.52 o0.001
55–69 years 1.22 2.04 4.23 4.54 5.73 9.22 8.74 o0.001
70–84 years 2.99 3.76 6.59 7.90 13.19 14.79 16.89 o0.001
85 and older 7.36 11.24 10.38 10.24 10.17 20.94 23.35 o0.001
Gender
Male 0.64 1.21 1.92 2.41 3.18 5.23 4.83 o0.001
Female 0.61 0.81 1.36 1.41 2.22 2.41 3.14 o0.001
Race
White 0.66 1.06 1.72 2.04 2.90 4.12 4.41 o0.001
Black 0.45 1.07 1.03 1.18 1.47 1.47 2.02 0.001
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Figure 1. Incidence of cutaneous B-cell lymphoma from the original nine Surveillance, Epidemiology,
and End Result registries, from 1973 to 2010. Trend line and original data points are shown.
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comprehensive cancer registries, did not
increase (Holterhues et al., 2010).
The strength of our study lies in the
use of population-based data, which
provide a large sample size with enough
statistical power to conduct incidence
analyses. In addition to the afore-
mentioned registration issues, another
limitation is underreporting. Four to six
percent of CLs categorized as CTCL in
the SEER database were found to have
B-cell lineage under the SEER variable
‘‘grade’’ (Criscione and Weinstock,
2007; Imam et al., 2013). In addition,
the rarity of CBCL makes trend evaluation
over time difficult. A third significant limi-
tation is that CBCL can represent primary
versus secondary skin involvement.
Although cases were counted using ana-
tomic sites coded for skin, it was difficult
to distinguish whether these patients had
codes of skin only (primary skin involve-
ment) or had non-skin sites in addition
(secondary skin involvement). Thus, there
is likely a mix of patients with primary
versus secondary skin involvement.
In conclusion, we report a stabili-
zation of overall CBCL incidence. The
causes for this trend change are
unknown but may include issues with
registration in the early years of SEER.
Further investigation is warranted to
determine the true etiologies of this
finding.
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TO THE EDITOR
Epidermolysis bullosa simplex (EBS) is a
group of genetic mechanobullous dis-
orders characterized by intraepidermal
cleavage. In the vast majority of cases,
basal EBS is caused by dominantly
inherited mutations in the keratin-5
and -14 genes (KRT5 and KRT14). How-
ever, the disease is genetically hetero-
geneous with about 25–30% of patients
lacking mutations in those genes (Rugg
et al., 2007; Bolling et al., 2011;
Bruckner-Tuderman and Has, 2012).
Well-defined subtypes of EBS are
associated with typical clinical features
and molecular pathology, but patients
with mild skin fragility often exhibit less
characteristic features rendering the
determination of the candidate gene
difficult (Groves et al., 2010; Liu et al.,
2012; Pigors et al., 2012; Kiritsi et al.,
2013). Recently, a homozygous frame-
shift mutation in the exophilin-5 gene
(EXPH5) was identified in three indivi-
duals of a consanguineous Iraqi family
with mild skin fragility (McGrath et al.,
2012). EXPH5 encodes the Rab27
effector protein called synaptotagmin-
like protein lacking c2 domains b
(Slac2b). This protein, also called
exophilin-5, is involved in intracellular
protein transport and exosome secretion
(Ostrowski et al., 2010). The mutation
found in the Iraqi family was located in
exon 6 of EXPH5, close to the 30 end,
leading to a premature termination
codon and the absence of the Slac2b
protein in the patient’s skin as shown by
immunolabeling with an antibody
recognizing the C terminus of Slac2b.
The clinical phenotype included dis-
crete trauma-induced skin blistering,
erosions and hemorrhagic crusting,
mild atrophy, and hypopigmentation.
This first case report prompted us to
sequence EXPH5 in a cohort of 35
patients with clinically suspected EBS
but without mutations in the KRT5 and
KRT14 genes. Here, we report the
second family with two EXPH5
mutations and extend on the clinical
and morphological spectrum of this rare
autosomal recessive EBS.
After obtaining written informed con-
sent, genomic DNA was extracted from
EDTA–blood samples obtained from 35
individuals and, whenever possible,
from their parents for mutation
analysis. Amplification and sequencing
of KRT5 and KRT14 were performed as
described previously (Arin et al.,
2010). Primers for all six exons andAccepted article preview online 4 September 2013; published online 17 October 2013
Abbreviations: EBS, epidermolysis bullosa simplex; EXPH5, exophilin-5 gene; KRT5, keratin-5 gene;
KRT14, keratin-14 gene; Slac2b, synaptotagmin-like protein lacking c2 domains b
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